Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM01 + tislelizumab in advanced solid tumors and lymphoma
CTR20220791Phase 2Active
- Sponsor
- ImmuneOnco
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of timdarpacept, tislelizumab in Nonhematologic neoplasms, lymphoma, bronchial carcinoma, head and neck squamous cell carcinoma (HNSCC), classical Hodgkin lymphoma (cHL), sponsored by ImmuneOnco. Started May 2022; status: active.
02
Drugs
timdarpacepttislelizumab
03
Conditions
Nonhematologic neoplasmslymphomabronchial carcinomahead and neck squamous cell carcinoma (HNSCC)classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on CTR20220791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220791.